LRRC25 and type 2 diabetes mellitus: Finally, we identified NCF1 as the core therapeutic target for T2D (OR = 1.09, 95% CI: 1.03-1.14, p = 1.85  ×10−3) and LRRC25 for T2D (OR = 0.96, 95% CI: 0.93-0.99, p = 3.44  ×10−2) and periodontitis (OR = 0.92, 95% CI: 0.84-0.99, p = 4.45  ×10−2).